The monoclonal origin of gonadotropin-secreting pituitary adenomas has been well demonstrated but only few molecular abnormalities have so far been recognized in these tumors. For many years, several authors have suggested a role for GnRH and/or GnRH receptors (GnRH-R) in the development of these pituitary adenomas. To test the hypothesis that mutant genes encoding a constitutively activated GnRH-R might be involved in the pathogenesis of these tumors, the sequence of the GnRH-R gene was analyzed in tumoral pituitary tissue obtained from ten patients (six female, four male). The pituitary gonadotropin-secreting adenoma was associated with in vivo hypersecretion of FSH, LH and/or free a-subunit (n ¼ 7) or was clinically silent (normal plasma levels of gonadotropins or free a-subunit, n ¼ 3). In all cases, immunocytochemical studies of the removed adenoma confirmed their gonadotroph nature by revealing positivity for FSH, LH and/or a-subunit. Genomic DNA was extracted from the pathological tissue obtained at neurosurgery. Eight sequencing primers were used to amplify the three exons of the GnRH-R gene from tumoral DNA. The entire coding sequence of the GnRH-R gene was sequenced in the ten adenomas. No mutation was found in any of the tumor specimens examined.
Introduction
The human gonadotropin-releasing hormone (GnRH) receptor (GnRH-R) is a member of the seven-transmembrane domain, G protein-coupled receptor family. It is encoded by a gene which comprises three exons, maps on the long arm of chromosome 4 (1) and couples principally to the inositol phosphate second messenger pathway. The G proteins associated with GnRH-R signal transduction have been identified as Gq/G 11 (2) . Hypothalamic GnRH pulse amplitude and frequency are critical for physiological regulation of serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels by normal pituitary gonadotrophs. Altered GnRH pulse characteristics may result in differential gonadotropin subunit gene expression and secretion in normal gonadotrophs (3) .
Gonadotropin-secreting pituitary adenomas, which represent the majority of the so-called clinically nonfunctioning pituitary adenomas (4, 5) , express gonadotropins and/or their free subunits (4, (6) (7) (8) (9) (10) . GnRH-R mRNAs have been detected in human gonadotroph adenomas (11) (12) (13) but the exact pathogenesis of these adenomas remains largely unknown (14) .
There is accumulating evidence from other G proteincoupled receptors that germline or somatic constitutive mutations, located either in Gs proteins, or in the receptor itself, are responsible for a number of hereditary or acquired endocrine disorders. Somatic mutations of the gene for the a-subunit of the Gs protein that stimulates adenyl cyclase and increases intracellular cAMP levels have been found in about 40% of the somatotroph tumors. Activating missense somatic mutations of the thyrotropin receptor, leading to constitutional increase in cAMP levels, have been detected in toxic autonomous thyroid adenomas (15) . As constitutive activation of the cell-signaling pathway coupled with the GnRH-R has been shown to have mitogenic and transforming effects in NIH3T3 mouse fibroblasts (16) , GnRH-R may have the potential to modulate tumor growth in addition to gonadotropin biosynthesis and secretion.
Thus, this led to the hypothesis that somatic constitutive mutations of the GnRH-R gene may be found in gonadotroph tumors.
Subjects and methods

Patients
Pituitary tumor specimens were obtained during surgery by transsphenoidal route in ten patients with gonadotropin-secreting adenomas. All tumors were macroadenomas. Specimens were immediately frozen in liquid nitrogen and stored at ¹70 ЊC until analyzed.
Assays and procedure of the dynamic tests
LH and FSH were measured using commercial kits. Free a-subunit and free LHb were measured with specific IRMAs as previously described (10) . Patients were all studied in the morning, recumbent after an overnight fast. Blood was collected 15 and 0 min before and 15, 30, 60 and 120 min after i.v. injection of 100 mg GnRH on one day, and after i.v. injection of 200 mg thyrotropin-releasing hormone (TRH) on another day.
Immunohistochemistry of the tumors
Tumors were fixed in Gerard's fluid and embedded in paraffin wax. Immunocytochemical studies of the tumor samples were carried out as previously described (10) .
DNA sequencing
Genomic DNA was extracted from the tumoral pituitary tissue. Eight sequencing primers were used to amplify the three exons of the GnRH-R gene (17) . PCR was performed for 30 cycles in a final volume of 50 ml containing 200 ng genomic DNA, 5 U Taq polymerase (Boerhinger-Mannheim, Mannheim, Germany) and 0.1 mmol/l of each primer for 30 cycles. Each cycle included incubations of 30 s at 94 ЊC, 30 s at 56 ЊC and 45 s at 72 ЊC. Double strand sequencing of the PCR products was performed using a dye primer cycle sequencing kit and a 373 A sequencer (Applied Biosystems, Foster City, CA, USA).
Results
Clinical and pathological data from the patients are shown in Table 1 . Some data from patients 1, 8 and 10 have been previously reported elsewhere (10) . Three patients (one premenopausal woman, #2; and two men, #8 and #10) had increased basal FSH levels. In one postmenopausal woman (#3) increased FSH levels together with 'normal' (but low for this age) LH levels were indicative of tumoral FSH hypersecretion. Increased basal plasma free a-subunit levels were found in two premenopausal women, either isolated (#6), or associated with supranormal LH (#1) levels, and in three men, either isolated (#5) or associated with increased FSH levels (#8 and #10). A paradoxical increase in free a-subunit, LH, FSH, and/or free LHb plasma levels following TRH was observed in four, two, two, and three patients respectively.
In all patients tested a positive in vivo response of gonadotropins or free a-subunit to stimulation with acute GnRH administration was observed.
The entire coding sequence of the GnRH receptor gene was sequenced in ten adenomas. No mutation was found in any of the tumor specimens studied. One silent polymorphism was detected at nucleotide 453 (C to T transition). It was also found in 3 out of 31 control subjects.
Discussion
There is now strong evidence for suggesting that in human pituitary adenomas, which are generally clonal in origin (18, 19) , the defect is located at the level of the pituitary and is caused by spontaneous or induced somatic mutations (14) . We have recently reported that inactivating mutations of the GnRH-R are responsible for familial hypogonadotropic hypogonadism (17) . Very recently, a truncated isoform of the human GnRH-R was detected in the intact pituitary cell (20) . This receptor displays an inhibitory effect when transfected with the full length GnRH-R in vitro. In the present study, the opposite hypothesis was tested, i.e. that mutant genes encoding a constitutively activated GnRH-R may be involved in the pathogenesis of gonadotroph tumors. The ability of GnRH to stimulate gonadotropin secretion from normal gonadotrophs under physiological conditions makes the GnRH-R a good candidate for implication in the pathogenesis of gonadotroph pituitary tumor (15) . GnRH-R gene expression has been previously studied in human gonadotroph adenomas (11) (12) (13) . The presence of GnRH-R mRNA predicted GnRH-stimulated increased secretion of gonadotropin by tumoral cells in vitro (11) . One might speculate that a mutant GnRH receptor could cause excessive gonadotropin secretion from dysregulated cells in vivo. It may also be involved in the usual persistent agonistic effects with sustained increases in gonadotropin secretion which are observed in most gonadotroph adenomas during continuous GnRH or GnRH agonist administration (21) (22) (23) . Lastly, such activating mutations of the GnRH-R gene, if they exist, would be a plausible explanation for tumor growth if one refers to studies performed in NIH 3T3 mouse fibroblasts where constitutive activation of Gqa, the G protein coupled with the GnRH-R, was shown to have proliferative effects (16) . However, it must be pointed out that, unlike growth hormone-releasing hormone (GHRH) for somatotrophs, there is no direct evidence as yet that GnRH is important for proliferation of gonadotrophs. Alternatively, mutations that activate gonadotroph-specific GnRH second messenger pathways could chronically down-regulate GnRH-R biosynthesis and desensitize neoplastic gonadotrophs to GnRH stimulation. In the present study, the coding region of the GnRH-R was found to be unaltered in ten gonadotroph adenomas indicating that the GnRH-R protein is likely to retain its normal structure in the majority of these tumors. In several other reports no common mutations or altered expression of a variety of candidate genes (reviewed in 14), including the TRH receptor for thyrotroph tumors (24, 25) or the GHRH receptor for somatotroph adenomas (26) were detected. The results of the present study are also consistent with a recent preliminary study, limited to exon 3 of the GnRH-R gene, in which no missense mutations were found in a series of gonadotroph adenomas (27) . One limitation of the present study might be the fact that the in vivo phenotype observed in all patients (positive response of gonadotropins or free a-subunit to acute administration of GnRH, which is the response observed in the majority of gonadotroph adenomas (4, 7, 8, 10)) would not be that resulting from activating mutations of GnRH-R, where an absent or poor response to GnRH might be expected. Thus it will be of interest to focus sequencing of the GnRH-R gene on this subset of gonadotropinomas.
The difficulties in finding an intrinsic defect associated with the development of gonadotroph adenomas contrast with the data obtained from studies performed in somatotroph adenomas. Phosphorylation (and hence activation) of cAMP response element-binding protein, whether promoted by constitutive Gsa overexpression (due to the presence of the mutant gsp oncogene) or stimulated by alternative, but yet undefined, mechanisms has been found in 100% of somatotropinomas (28) . Conversely, for gonadotroph pituitary adenomas as well as for corticotroph, lactotroph, or thyrotroph adenomas, the fundamental defect(s) leading to tumoral formation remain(s) speculative.
In conclusion, mutations in the GnRH-R coding sequence occur infrequently if at all in human gonadotroph pituitary adenomas. The potential role of defects in the expression of GnRH-R or Gq/G 11 , dysregulation of downstream components, inappropriate activation of other stimulatory pathways or loss of inhibitory inputs, deserves further study.
